Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer's disease.

ABSTRACT:

Background

In Alzheimer's disease, amyloid- β (A β) peptides aggregate in the lowering CSF amyloid levels - a key pathological hallmark of the disease. However, lowered CSF amyloid levels may also be present in cognitively unimpaired elderly individuals. Therefore, it is of great value to explain the variance in disease progression among patients with A β pathology.

Methods

A cohort of n=2293 participants, of whom n=749 were A β positive, was selected from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database to study heterogeneity in disease progression for individuals with A β pathology. The analysis used baseline clinical variables including demographics, genetic markers, and neuropsychological data to predict how the cognitive ability and AD diagnosis of subjec

SUBMITTER: Dansson HV 

PROVIDER: S-EPMC8422748 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature